# DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris

Study · id `cardio:ct-nct03633890` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03633890](<https://clinicaltrials.gov/study/NCT03633890>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03633890

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 102 participants.

## Technical summary

Registry record NCT03633890. Randomized; double masking; primary purpose treatment. Start 2018-08 (anticipated); primary completion 2019-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 102 participants (planned count; ClinicalTrials.gov record NCT03633890, source copy `cardio:ctgov-nct03633890-2018-08-16`, retrieved 2026-10-26)
- Planned start: 2018-08 (anticipated) (ClinicalTrials.gov record NCT03633890, source copy `cardio:ctgov-nct03633890-2018-08-16`, retrieved 2026-10-26)
- Primary completion: 2019-02 (anticipated) (ClinicalTrials.gov record NCT03633890, source copy `cardio:ctgov-nct03633890-2018-08-16`, retrieved 2026-10-26)
- Completion: 2019-02 (anticipated) (ClinicalTrials.gov record NCT03633890, source copy `cardio:ctgov-nct03633890-2018-08-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03633890, source copy `cardio:ctgov-nct03633890-2018-08-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03633890-2018-08-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: DaZhu Rhodiola Rosea Capsule for Coronary Artery Disease With Angina Pectoris
- Condition: Coronary Artery Disease
- Intervention (Drug): DaZhu Rhodiola Rosea Capsule
- Intervention (Drug): DaZhu Rhodiola Rosea Simulation Capsule
- Lead sponsor: Beijing Anzhen Hospital
- Lead sponsor class: OTHER
- Collaborator: Jiangsu Kangyuan Pharmaceutical Co. Ltd
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Beijing Anzhen Hospital (`cardio:org-beijing-anzhen-hospital`)

## Provenance

Content hash: 97ead849aef84c102c65a5d7976a197f9723e58a9ac83d6fd5fab89d45014f9d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
